Expression of GPR34 in microglia remains stable in human Alzheimer’s disease - Takeaways - MDSpire

Expression of GPR34 in microglia remains stable in human Alzheimer’s disease

  • By

  • Sophie Seiffer

  • Jonas Rotter

  • Jana Brendler

  • Albert Ricken

  • Zoe Detzer

  • Max Braune

  • Torsten Schöneberg

  • Angela Schulz

  • Karsten Winter

  • Ingo Bechmann

  • June 15, 2026

  • 0 min

Share

  • 1

    Alzheimer's disease is characterized by synaptic dysfunction, neuronal loss, and the accumulation of hyperphosphorylated tau and amyloid-β peptides.

  • 2

    GPR34 is a microglial gene that is downregulated with aging and may play a role in neuroinflammation and cognitive impairment in Alzheimer's disease.

  • 3

    Transgenic mouse models of Alzheimer's disease show that GPR34 deletion improves learning and memory while reducing neuroinflammation.

  • 4

    The study aims to assess whether GPR34 expression and microglial changes in mouse models are also present in human Alzheimer's disease cases.

  • 5

    Findings suggest that GPR34 signaling may contribute to Alzheimer's pathogenesis and could be a potential therapeutic target.

Original Source(s)

Expression of GPR34 in microglia remains stable in human Alzheimer’s disease

  • by Sophie Seiffer, Jonas Rotter, Jana Brendler, Albert Ricken, Zoe Detzer, Max Braune, Torsten Schöneberg, Angela Schulz, Karsten Winter, Ingo Bechmann

  • June 15, 2026

Related Content

Editorial: Transforming dementia caregiving through assistive technologies

Alternative splicing-based therapeutics for neurodegenerative diseases: a dual-database bibliometric and NLP-driven analysis (2000–2025)

Alzheimer’s disease and related dementia: evaluation, diagnosis and acute care management